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ABSTRACT 
ISOLATION AND CHARACTERIZATION OF HUMAN T-CELL LYMPHOTROPIC 
VIRUS TYPE-1 FROM PATIENTS WITH TROPICAL SPASTIC PARAPARESIS. 
Guy M. McKhann II and Clarence J. Gibbs Jr., Laboratory of Central Nervous 
System Studies, National Institutes of Health, Bethesda, MD. (Sponsored by G. 
D. Edith Hsiung, Department of Laboratory Medicine, Yale University). 
Endemic tropical spastic paraparesis/HTLV-l associated myelopathy 
(TSP/HAM) is a slowly progressive chronic neurological disorder that is 
manifested clinically by spastic paraparesis frequently in association with bowel 
and bladder dysfunction. It is one of the most common chronic neurologic 
disorders in many endemic foci around the world. Human T-lymphotropic virus 
type-1 (HTLV-I) has been etiologically associated with TSP/HAM based primarily 
on the high prevalence of antibodies to HTLV-I in the serum and CSF of 
affected patients. We report here the isolation of HTLV-I from peripheral blood 
lymphocytes and cerebrospinal fluid derived mononuclear cells of TSP/HAM 
patients by stimulation with interleukin-2 and cocultivation with umbilical cord 
blood mononuclear cells. Established cell lines contained HTLV-I antigen as 
demonstrated by immunoflourescence and cell-associated virus particles as 
observed by electron microscopy; low level reverse transcriptase activity was 
detected in cultures expressing viral antigens. Virus infected cultures were 
transformed in vitro as determined by their loss of contact inhibition and their 
continuous growth in the absence of exogenous IL-2. Of particular significance 
was our isolation of HTLV-I from three family members with TSP/HAM of varying 
duration and clinical severity. 
This study resulted in the first isolation of virus from a cluster of 

TSP/HAM patients within the same family, the first isolation of virus from a 
childhood case of TSP/HAM, and the first in vitro transformed HTLV-l-infected 
cells from TSP/HAM patients. In addition, the methodology applied in this 
investigation subsequently has been used to consistently isolate virus from 
HTLV-I infected persons from widely separated geographic locations. This work 
supports a causative role for HTLV-I in the pathogenesis of TSP/HAM and helps 




Endemic tropical spastic paraparesis (TSP) is the most common chronic 
neurological disorder in many tropical and subtropical regions of the world 
[Rodgers-Johnson et al, 1989b]. This disorder is characterized by slowly 
progressive spastic paraparesis frequently in association with bowel and 
bladder dysfunction. It occurs in geographically widely separated endemic foci 
[Roman, 1987]. A number of processes have been postulated to be involved in 
the pathogenesis of TSP in individual endemic areas including nutritional 
deficiencies [Cosnett, 1965; Grieve et al, 1967], neurotoxic ingestions 
[Cruickshank, 1956], and a variety of microbial infections [Minchin, 1940; 
Rodgers, 1965; Robertson and Cruickshank, 1972; Roman et al, 1987]. None of 
these hypotheses has been able to account for the disease in all of the 
geographic foci in which it occurs [Roman et al, 1985b]. 
Over the past five years, it has been established that TSP patients have a 
high prevalence of antibodies to human T-lymphotropic virus type-1 (HTLV-I) in 
both serum and cerebrospinal fluid (CSF) [Rodgers-Johnson et al, 1988b]. This 
important finding is the one piece of etiologic evidence that unifies the varied 
patient populations with endemic TSP [Rodgers-Johnson et al, 1985]. 
Additionally, patients from nontropical southern Japan with a chronic 
neurological disorder that is clinically and histopathologically indistinguishable 
from TSP also have antibodies to HTLV-I in their serum and CSF [Osame et al, 
1986a]. This syndrome, HTLV-I associated myelopathy (HAM), is now felt to be 
identical to TSP [Roman and Osame, 1988]. Together, these chronic 
encephalomyeloneuropathies are designated TSP/HAM and have been found 
in more than 40 countries [Rodgers-Johnson et al, 1990]. 
HTLV-I, the first retrovirus isolated from humans [Poiesz et al, 1980a], 
was previously implicated as the causative agent of adult T-cell leukemia (ATL) 
[Yoshida et al, 1984; Gallo, 1985]. It had never been linked to neurologic 
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disease until its serologic association with TSP/HAM was demonstrated. 
At the time this project was initiated, serologic evidence strongly 
associated HTLV-I with TSP/HAM. Virus isolation was an essential step in 
establishing an etiologic role for HTLV-I in the pathogenesis of TSP/HAM. 
However, isolation of virus from patients with this disease was previously 
reported to be difficult, and only individual case reports of successful isolation 
existed [Hirose et al, 1986; Defreitas et al, 1987; Rodgers-Johnson, 1988]. 
The purpose of this investigation was to isolate HTLV-I from peripheral 
blood lymphocytes and mononuclear cells of the CSF of TSP/HAM patients. 
Utilizing techniques similar to those that were previously successful in isolating 
HTLV-I from ATL patients, isolation was accomplished through cocultivation of 
patient cells with umbilical cord blood lymphocytes in the presence of 
interleukin-2. This study proved to be especially significant in that it led to the 
isolation of HTLV-I from three family members living in the endemic TSP focus 
of Tumaco, Colombia with spastic paraparesis of varying duration and severity. 
Successful isolation of the virus from the 13-year-old son represents the 
youngest TSP/HAM patient isolation to date. The techniques used in this 
investigation have subsequently been applied to allow consistent isolation of 
virus from HTLV-I infected persons. 
Nomenclature 
The nomenclature of chronic tropical neurological disorders of uncertain 
etiology is confusing and requires explanation. These disorders have been 
reported under various designations for the past 100 years but are now divided 
into two clinical groups. Tropical ataxic neuropathy (TAN) is an endemic form of 
disease manifested by predominately proprioceptive dysfunction with variable 
mild pyramidal signs and optic and auditory nerve involvement. Tropical spastic 
paraparesis (TSP) occurs in two forms, epidemic and endemic. Both epidemic 
and endemic TSP present clinically as a predominately spastic disorder with 
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frequent bowel and bladder dysfunction and variable posterior column and 
spinothalamic tract involvement [Rodgers-Johnson, 1988]. HTLV-I associated 
myelopathy (HAM) is a disorder that is endemic in non-tropical regions of Japan 
and is identical to the endemic form of TSP [Roman and Osame, 1988]. 
The terms chronic HTLV-I myelitis [Roman, 1989] and HTLV-I 
encephalomyeloneuropathy [Rodgers-Johnson et al, 1989] have recently been 
suggested to incorporate TSP and HAM under the same heading. However, the 
World Health Organization currently recognizes TSP/HAM as the official 
nomenclature for this disease process, and it is this designation that is used 
throughout the thesis. 
Historical background 
Chronic tropical neurological disorders of uncertain etiology were first 
reported over one hundred years ago by Strachan who described 510 
Jamaicans with "a form of multiple neuritis prevalent in the West Indies" 
[Strachan, 1888; Strachan, 1897]. These patients had combined sensorimotor 
findings predominated by burning pain of the soles of the feet, ataxic gait, 
impaired lower extremity proprioception, and decreased or absent knee jerk 
reflexes. Strachan believed malaria to be responsible [Strachan, 1888], but the 
clinical picture was also compatible with arsenic intoxication from agricultural 
pesticides [Heyman et al, 1956]. These cases were reviewed twenty years later 
by Scott, and he concluded that a variety of clinical entities were involved 
including beri-beri, pellagra, and "Jamaican peripheral neuritis" [Scott, 1918]. 
In 1918, Scott described an acute outbreak of "central neuritis" in 21 
Jamaican sugar cane cutters whose clinical picture was similar to Strachan's 
patients. Although he felt that his patients represented an acute form of 
Strachan's syndrome resulting from toxic ingestion, the acute clinical 
presentation suggested a postviral acute sensory neuronopathy syndrome 
[Sterman et al, 1980; Roman et al, 1985b]. The first detailed autopsies were 
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performed on two of Scott’s patients who died with terminal diarrhea. The 
pathologic report detailed widespread changes consisting of diffuse spinal cord 
fatty degeneration and fibrosis that was most marked in the posterior columns 
and cerebellar tracts, extensive dorsal root ganglion fatty deposition and 
pigmentation, and optic greater than auditory nerve involvement [Scott, 1918]. 
Since these initial two reports, hundreds of cases of unusual chronic 
tropical neurologic disorders (later designated tropical myeloneuropathies 
[Roman, 1985b]) with similar clinical manifestations were described 
predominantly in underdeveloped areas of Africa [Wright, 1928; Stannus, 1930] 
and World War II prisoners [Cruickshank, 1946; Gibberd, 1980; Gill and Bell, 
1982] These reports causally implicated vitamin deficiencies [Wright, 1928; 
Wright, 1936], malnutrition [Walters, 1947; Money, 1959], and/or tropica! 
malabsorption (tropical sprue) [Keele et al, 1946; Elder, 1947]. Some 
investigators suggested that toxic ingestion or exposure was responsible 
[Cruickshank, 1946]. 
A clinical classification of this group of disorders was finally made in 
1956 by Cruickshank who reported on 100 Jamaican patients seen at the 
University of West Indies over a three year period. He detailed two clinical 
pictures: 80% of his patients had predominantly lower limb spasticity and 
weakness while 20% were characterized by lower limb ataxia [Cruickshank, 
1956]. Cruickshank's observations paved the way for the division of tropical 
myeloneuropathies into tropical ataxic neuropathy (TAN) and the two forms of 
tropical spastic paraparesis (TSP), epidemic and endemic. 
Tropical Ataxic Neuropathy 
TAN, a term coined by Osuntokun [Osuntokun, 1968], is an endemic form 
of myeloneuropathy most prevalent in parts of Africa. Patients typically complain 
of "burning feet" or other lower extremity paresthesias or dysesthesias and on 
examination are found to have severe impairment of position, vibration, touch, 
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and pressure sensation that is more pronounced in the distal lower extremities. 
Ankle and knee jerk reflexes are diminished or absent. Mild pyramidal signs 
and optic and auditory nerve involvement are sometimes present [Roman et al, 
1985b]. The etiology of TAN in certain foci remains unclear, but in Nigeria and 
other parts of Africa, TAN has been clearly demonstrated to result from ingestion 
of improperly prepared or immature cassava root at times of food shortage. 
Cassava, a root vegetable that exists in two forms, Manioc utilissima and 
Manioc palmata. is the dietary staple in these regions. Improperly prepared or 
immature cassava contains high levels of cyanogenic glucosides, consumption 
of which results in TAN [Osuntokun, 1985; Cliff et al, 1985]. 
Epidemic Tropical Spastic Paraparesis 
In contrast to the proprioceptive dysfunction with sensory ataxia that 
predominates in TAN, lower limb spastic paraparesis with weakness and 
hyperreflexia is characteristic of endemic and epidemic TSP. Epidemic TSP, 
which has only been reported from Africa, presents with the rapid onset of 
bilateral spastic paraparesis, sometimes in association with visual disturbance 
and speech disorders. Like TAN, epidemic TSP usually results from 
consumption of undercooked or poorly prepared cassava at times of drought 
[Casadei et al, 1984], although an infectious agent is still thought to be the 
cause in Zaire [Carton et al, 1986]. 
Endemic Tropical Spastic Paraparesis 
Epidemiology 
Following the initial description of Jamaican neuropathy by Cruickshank 
[Cruikshank, 1956], endemic foci of TSP were reported in various parts of the 
world under geographically specific designations including South African 
paraplegia [Cosnett, 1965], Seychelles paraplegia [Roman et al, 1987a; Roman 
et al, 1987b], South Indian paraplegia [Mani et al, 1969], and 'paraparesis 
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espastico del Pacifico' in Colombia [Zaninovic et al, 1981]. Additionally, 
Osame described clinically similar HAM patients from temperate regions of 
southern Japan [Osame et al, 1986a; Osame et al, 1987a]. It was initially 
thought that HAM and TSP were different disorders and that TSP was confined 
to tropical regions of the world, but it is now clear that TSP is found in some 
nontropical areas (Figure 1) [Rodgers-Johnson et al, 1989] and that TSP and 
HAM are the same disease [Roman and Osame, 1988]. 
Consistent with the population distribution of the endemic foci, most TSP 
patients are black and from lower socioeconomic groups in tropical regions 
[Rodgers-Johnson et al, 1990]. However, the ethnic, socioeconomic, and 
geographic distributions of the disease were expanded when it was realized 
that TSP and HAM are the same disease and that TSP is not restricted to 
tropical regions. In addition to Japanese and blacks in endemic regions, the 
disease has been reported in Indians, Chinese, mulattoes, and Caucasians 
[Roman, 1987], in Caribbean migrants to the United States [Bhagavati et al, 
1988] and the United Kingdom [Cruickshank et al, 1989], and also in blacks in 
the United States who have never travelled to endemic areas [Bhagavati et al, 
1988]. A non-tropical endemic foci of TSP/HAM has been recognized in Chile 
[Cartier-Rovirosa et al, 1989], and the disorder has been reported in upper and 
middle class Caucasians in the desert climate of Lima, Peru [Johnson et al, 
1988]. Isolated cases have been reported in southern Italy [Annunziata et al, 
1988] and France [Gessain et al, 1988]. 
The age of onset of TSP/HAM is usually from 35-49 years, although 
patients have been less than 20 years and over 70 years at the time of 
diagnosis. A few childhood cases have been reported from Japan, and a 
13-year-old Colombian boy with early clinical signs and antibodies to HTLV-I in 
both serum and CSF was reported as part of this study [McKhann et al, 1989]. 
There is a female preponderance of approximately 3 to 1 in the majority 
of endemic areas, possibly because sexual transmission is predominately 

unidirectional from males to females [Kajiyama et al, 1986]. Some earlier 
smaller studies of the same populations reported equal sex incidence 
[Montgomery and Cruickshank, 1964; Roman et al, 1987b, Rodgers-Johnson, 
1990]. 
The prevalence of the disease varies somewhat between endemic foci 
from about 50 per 100,000 in the northern Atlantic region of Martinique to 128 
per 100,000 in the Seychelles Islands. In Tumaco, Colombia the prevalence for 
the total population is 91 per 100,000 but increases to 281 per 100,000 if only 
those older than 25 are considered. These significant prevalence rates are 
comparable to the highest known prevalence of multiple sclerosis of 128 per 
100,000 in the Orkney and Shetland Islands of Scotland [Roman, 1988]. 
Clinical Characteristics of TSP/HAM 
Although there is variability, the predominant clinical features of 
TSP/HAM worldwide include the gradual onset of lower extremity weakness 
frequently in association with sensory symptoms ranging from burning to 
numbness to pins and needles [Rodgers-Johnson et al, 1989a]. Lumbosacral 
pain and urinary symptoms including frequency, urgency, nocturia, and 
incontinence are common; impotence, decreased libido, and constipation also 
occur frequently [Cruickshank, 1956; Montgomery and Cruickshank, 1964; 
Vernant et al, 1987]. Other variable manifestations include decreased hearing 
or vision and unsteadiness of gait. 
On examination, patients have a spastic paraparesis with lower 
extremity hyperreflexia and a spastic gait. The spastic paraparesis usually 
develops insidiously and may be initially unilateral. Most patients have extensor 
plantar responses, bilateral clonus, and upper extremity hyperreflexia, but less 
than 50% of patients have arm weakness. Vibration sense is diminished slightly 
more frequently than position sense, and peripheral sensory changes including 
a sensory level or signs consistent with a root lesion may occur [Osame et al, 
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1987b; Rodgers-Johnson et al, 1988a; Said et al, 1988]. Other variable signs 
include diminished abdominal reflexes, nystagmus, intention tremor, optic 
atrophy, nerve deafness, ptosis, recurrent laryngeal nerve palsy, and facial 
weakness. Cognitive functions are preserved [Montgomery and Cruickshank, 
1964; Rodgers, 1965; Zaninovic, 1988] (Table 1). 
The characteristic clinical course of TSP is a slow progression over months 
to years, often with periods of plateau for several years. Severe disability 
usually results with 90% of patients requiring assistance to walk and 50% of 
patients wheelchair bound at 10 years [Cruickshank, 1989]. Patients have 
survived for up to 55 years after diagnosis [Osame et al, 1987b]. However, acute 
events similar to transverse myelopathy or vascular events have been reported. 
Prognosis is worse in those who become rapidly paraplegic because of 
predisposition to urinary tract infections or pulmonary emboli [Rodgers, 1965]. 
Pathology 
There have been remarkably few postmortem studies of TSP/HAM 
patients. Nevertheless, pathologic findings were consistent in an early series of 
15 Jamaican cases [Robertson and Cruickshank, 1972], a later report of 2 
Jamaican cases [Piccardo et al, 1988], in single autopsies from the Seychelles 
[Roman et al, 1987a] and South India [Mani et al, 1941], and in Japanese 
reports [Akizuki et al, 1987; Nakazato et al, 1987]. The typical pathologic 
features consist of widespread meningoencephalomyelitis and spinal cord 
demyelination. The meningoencephalomyelitic changes, which are greatest at 
the spinal cord level, consist of perivascular inflammatory cuffing with plasma 
cells, lymphocytes, and histiocytes; microvascular proliferation; reactive 
astrocytic gliosis; and perivascular fibrosis with small vessel hyalinization. The 
spinal cord demyelination usually affects the lateral columns more than the 
posterior columns (Figure 2). In an early report on pathology, Robertson and 
Cruickshank commented on the similarity of the widespread central nervous 
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system disease in TSP/HAM to meningovascular syphilis. However, endarteritis 
obliterans, miliary gummata and other pathologic features characteristic of 
syphilis were never seen [Robertson and Cruickshank, 1972]. In patients with 
long term progressive TSP/HAM [Roman, 1988], the spinal cord pathology may 
resemble the vacuolar myelopathy seen in patients with the acquired 
immunodeficiency syndrome [Petito et al, 1985]. 
Laboratory Investigations and Diagnostic Tests 
Most routine laboratory tests are normal in TSP/HAM including blood and 
urine chemistries, erythrocyte sedimentation rate, vitamin B12 level, and 
nutritional and metabolic parameters. Peripheral blood smears can be helpful in 
that 1-3% of lymphocytes may be atypical with convoluted rosette type nuclei 
[Rudge, 1989]. CSF parameters are frequently normal although a moderate 
predominately lymphocytic CSF leucocytosis with increased protein has been 
seen in 16-57% of patients [Rodgers, 1965; Vernant et al, 1987]. Atypical 
lymphocytes similar to those seen in peripheral smears are sometimes found in 
the CSF [Osame et al, 1986; Osame et al, 1987b]. CSF gamma globulin is 
frequently increased, and oligoclonal bands are seen [Roman, 1988]. 
Visual evoked potential studies are abnormal in up to 50% of patients 
[Cruickshank et al, 1989], although much lower frequencies have been reported 
[Bhagavati et al, 1988]. The marked symmetry of these latencies suggests that 
multiple small demyelinating lesions are present within both optic nerves, a 
finding that has been previously described in pathologic specimens. Minor 
brain stem auditory evoked potential abnormalities are commonly seen 
consisting of prolongation of various brainstem components with a normal 
component 1. Somatosensory evoked potentials are usually abnormal in testing 
of both the upper and lower extremities in a pattern that suggests bilateral 
involvement of the fasciculus gracilis [Cruickshank et al, 1989]. Although not a 
consistent finding in all studies, abnormal conduction velocities along sural and 
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peroneal nerves have been reported. These abnormal F wave latencies are 
most compatible with patchy demyelination/remyelination of peripheral nerves 
resulting from vasculitis along the vasa nervosum [Said et al, 1988]. 
Magnetic resonance imaging of patients, in comparison to appropriately 
age matched controls, has detected both cerebral and spinal cord lesions 
[Furukawa et al, 1989]. In the brain, minor periventricular and supratentorial 
white matter abnormalities are seen, occasionally accompanied by posterior 
fossa lesions. These brain lesions are usually less extensive than those seen in 
multiple sclerosis (MS) patients with a corresponding level of clinical disability 
[Cruickshank et al, 1989]. Results of magnetic resonance imaging (MRI) must be 
interpreted in relation to age because white matter abnormalities are found in 
over 30% of apparently normal individuals over 50 years [Brant-Zawadski et al, 
1984]. Spinal cord change visualized by MRI, if present, is limited to dorsal 
column atrophy. Areas of increased signal in the spinal cord, as are sometimes 
found in MS, are not seen in TSP/HAM [Rudge, 1989]. 
Etiology 
Early studies in Jamaica [Cruickshank et al, 1961; Rodgers, 1965] and 
South India [Mani et al, 1969] and more recent case control studies from 
Colombia [Roman et al, 1985 ] and the Seychelles [Roman et al, 1987a] failed 
to implicate diet, nutritional defiencies, neurotoxin exposure, housing, 
occupation, farming, pets, habits, or geographic location as possible contribtory 
factors in TSP pathogenesis. The etiology of TSP thus remained unclear. 
A possible infectious etiology for the disease was first hypothesized three 
decades ago. Because of the pathologic similarity to meningovascular syphilis 
and because the geographic distribution of the disease on Jamaica is the same 
as that of previous yaws endemia, treponemal associations were postulated 
including atypical syphilis [Rodgers, 1965] and yaws [Montgomery, I960]. 
(Yaws is a non-venereal spirochetal disease caused by Treponema pertenue 
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that is serologically indistinguishable from syphilis. It was previously prevalent 
in many areas where TSP/HAM is now found.) Early treponemal studies 
detected positive serology in greater than 60% of sera and 26.1% of CSF 
samples from Jamaican patients [Rodgers, 1965], in greater than 60% of sera 
and 19% of CSF samples from Colombian patients [Rodgers-Johnson et al, 
1986], and in more than 42% of patients living in the Seychelles Islands [Roman 
et al, 1987a]. Early serologic testing in Martinique, South Africa, and India did 
not support a treponemal etiology [Vernant et al, 1987; Cosnett et al, 1965; 
Mani et al, 1969]. 
More recently, further testing detected Treponema pallidum antibodies in 
11 of 24 sera but only 1 of 24 CSF samples from Jamaican patients 
[Rodgers-Johnson et al, 1985]. Furthermore, treponemal infection prevalence 
has declined in Jamaica over the past three decades while no corresponding 
decrease in the prevalence of TSP has been seen [Rodgers-Johnson, 1989]. 
An unexplained finding was the presence of antibodies to Borrelia burgdorferi, 
the etiologic agent in Lyme disease, in 44% and 24% of Seychelles and 
Jamaican sera, respectively [Roman et al, 1987a; Rodgers-Johnson et al, 1986]. 
A viral etiology for TSP was first postulated by Montgomery and 
Cruickshank in 1964 based on pathologic findings [Montgomery and 
Cruickshank, 1964]. Mani further noted in 1969 that Indian TSP was similar both 
clinically and histopathologically to visna-maedi lentivirus induced sheep 
encephalomyelopathy [Mani et al, 1969]. In addition, although most TSP 
patients' CSF samples are normal, studies from Jamaica and Martinique 
detected a predominately lymphocytic pleocytosis with increased protein in 
16% to 57% of patients. Despite these suggestions of infection, early virological 
investigations were consistently negative [Montgomery and Cruickshank, 1964; 
Rodgers, 1965; Montgomery, 1986]. 
The first serologic evidence of viral involvement in TSP was reported by 
Greaves £i ai in 1984 who noted high antibody titers to human T-cell 
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lymphotropic virus type I (HTLV-I) in one TSP patient as part of a large HTLV 
serological study in the United Kingdom [Greaves et al, 1984]. However, it was 
not until Gessain el al detected IgG antibodies to HTLV-I in 68% of patients with 
TSP in Martinique in 1985 that HTLV-I was considered as a possible causative 
agent [Gessain et al, 1985]. The significance of these results was greatly 
enhanced by the detection of high titers of HTLV-I antibodies in both serum and 
CSF of patients from two separate TSP foci, Jamaica and Colombia 
[Rodgers-Johnson et al, 1985]. In addition, Osame filal in 1986 reported high 
titers of HTLV-I antibodies in serum and CSF from 6 of 6 patients from 
non-tropical southern Japan with a chronic myelopathy clinically and 
histopathologically similar to TSP that they designated HAM [Osame et al, 
1986]. 
Antibodies to HTLV-I were subsequently confirmed in the sera of a high 
percentage of TSP/HAM patients from all endemic foci tested, ranging from 80% 
in Martinique and the Seychelles to 92% in Jamaica to 98% in Colombia to 
100% in Japan. In addition, 89% of Jamaican and 96% of Colombian TSP/HAM 
patients tested in our laboratory were found to have anti-HTLV-l reactivity not 
only in their serum but in their CSF as well. In contrast, the prevalence of 
antibodies to HTLV-I of the general population in endemic areas ranged from 
3-5% in Martinique and Jamaica to 12% in the Seychelles to 16% in southern 
Japan [Montgomery, 1989] (Table 2). 
Evidence for HTLV-I Infection in TSP/HAM 
In addition to the strong serologic evidence etiologically associating 
HTLV-I with TSP/HAM, additional evidence included: 
1) Intrathecal synthesis of IgG antibodies to HTLV-I in patients as 
evidenced by the presence of oligoclonal bands of HTLV-I specific IgG in CSF. 
The oligoclonal band pattern against HTLV-I in CSF differed from that found in 
serum. The CSF to serum albumin ratio was normal in these studies indicating 
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intact blood brain barrier function [Osame et al, 1987b; Ceroni et al, 1988]. 
2) The presence of abnormally activated CD4+ lymphocytes with 
lobulated nuclei in CSF and sera.. These cells were morphologically 
indistinguishable from HTLV-I infected peripheral blood lymphocytes from ATL 
patients [Osame et al, 1986a; Johnson et al, 1988; Sarin et al, 1989] (Figure 3). 
3) Increased numbers in peripheral blood of large CD3+ mononuclear 
cells expressing IL-2 receptor molecules consistent with HTLV-I mediated 
activation of the gene encoding the alpha subunit of the IL-2 receptor [Jacobson 
et al, 1988b]. 
4) Elevated spontaneous lymphoproliferative response in vitro of 
lymphocytes from peripheral blood of patients indicating abnormal activation of 
these cells [Jacobson et al, 1988b; Itoyama et al, 1988] . 
5) Demonstration of HTLV-I antigens in peripheral blood lymphocytes by 
immunoflourescent staining using polyclonal antiserum from a chimpanzee 
infected with HTLV-I [Piccardo et al, 1988]. 
6) Three independent reports of virus isolation of HTLV-I or a HTLV-I like 
virus from, respectively, the CSF of a HAM patient [Hirose et al, 1986], 
peripheral blood of a patient with a chronic myelopathy of unknown etiology 
[Defreitas et al, 1987], and CSF of a Jamaican TSP patient [Rodgers-Johnson et 
al, 1988a]. 
Despite this evidence, isolation of HTLV-I from peripheral blood 
lymphocytes or CSF mononuclear cells of patients was reported to be difficult 
[Hirose et al, 1986; DeFreitas et al, 1987]. This was also the case in our 
laboratory as virus was initially successfully isolated from only 1 of 30 
specimens from Jamaica or Colombia. 
Human T-cell Lvmphotropic Virus Type-1 (HTLV-I) 
Endemicitv and Modes of Transmission 
HTLV-I, the first retrovirus isolated from humans, is a type C retrovirus. 
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Antibody to this rather ubiquitous virus has been detected in 3-16% of the 
general population in southern Japan, the Caribbean, West Africa, and South 
America. Additionally, infection has been detected in 3-6% of asymptomatic 
Caribbean immigrants to the United Kingdom and in 4-5% of male 
homosexuals at risk for AIDS. Testing for antibody in blood donors in the United 
States has revealed only 0-0.1% positivity [Weber, 1989], while 1.9% of blood 
samples assayed at the Fukuoka Red Cross Blood Center in Japan were 
positive in 1983 [Okochi et al, 1984]. Following the initiation in 1986 of antibody 
screening of blood samples in Japan, the seroconversion rate resulting from 
transfusion decreased from 8.9% to 0.08% in Kyushu University Hospital 
[Okochi and Sato, 1989]. 
HTLV-I is unusual in that it remains endemic in geographic foci for long 
periods of time without any known vector of transmission with the exception of 
man. Several modes of transmission of HTLV-I have been implicated. HTLV-I 
seroconversion following blood transfusion was well demonstrated in Japan to 
be mediated by viable T-cells but not by plasma [Okochi et al, 1984]. 
Additionally, early epidemiologic studies in Japan showed an increased 
prevalence of HTLV-I in females in endemic areas [Tajima et al, 1982]. From 
these studies sexual transmission with a greater frequency of transmission from 
males to females than females to males was suspected. Evidence of sexual 
transmission included the observation that most wives of HTLV-I positive 
husbands seroconverted [Tajima et al, 1982], the demonstration of HTLV-I 
infected cells in semen [Nakano et al, 1984], and the finding of increased rates 
of seropositivity in sexually active homosexuals at risk for AIDS (Tedder et al, 
1984; Robert-Guroff et al, 1984] and in promiscuous intravenous drug users in 
comparison to nonpromiscuous matched controls [Rezza et al, 1988]. The 
possibility of transmission from infected husband to wife over a ten year period 
was calculated to be 60.8% in contrast to the 0.4% chance of transmission from 
infected wife to husband over the same time period [Kajiyama et al, 1986]. 
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In addition to blood borne and sexual horizontal routes of transmission, 
vertical transmission was suggested by reports of intra-familial clustering of 
HTLV-I carriers [Ichimaru et al, 1979] and of an association between carrier 
mothers and their children [Tajima et al, 1982]. Japanese investigators recently 
demonstrated by seroepidemiologic and virologic studies that transmission from 
mother to child by breast feeding is a major natural route [Hino and Doi, 1989]. 
Retroviral Characteristics 
HTLV-I is characterized as a single stranded RNA virus that encodes a 
RNA dependent DNA polymerase (reverse transcriptase). Following infection of 
a susceptible cell, the reverse transcriptase "retrotranscribes" the viral RNA into 
proviral DNA for integration into the host's cellular genome. Following 
integration, the provirus has one of three fates: 1) to remain latent in infected 
cells either thru host or viral mediated inhibition of viral transcription; 2) to 
replicate resulting in viral progeny production and death of the host cell when 
the host is unable to inhibit viral transcription; and 3) to induce host cell 
transformation resulting in tumoral proliferation [de The, 1989]. 
There are three subfamilies of retroviruses. Spumavirinae have no known 
associated disease. In animals, Qncornavirinae are associated with 
hematological proliferations and connective tissue tumors, while Lentivirinae 
are associated with neurologic and/or pulmonary diseases [de The, 1989]. No 
retroviruses were known to infect humans until Gallo and his associates 
developed the methodology for successfully culturing T-cells in the presence of 
interleukin II (T-cell growth factor) [Morgan et al, 1976; Poiesz et al, 1980b]. 
Soon after this important advance, HTLV-I was isolated in 1980 by Poiesz, 
Gallo, el a[ from a patient with cutaneous T-cell lymphoma (CTCL) [Poiesz et al, 
1980a]. A similar retrovirus, HTLV-II, was subsequently isolated from a patient 
with a T-cell variant of hairy cell leukemia [Kalyanaraman et al, 1982b]. Both 
HTLV-I and HTLV-II are oncornaviruses and as such are able to induce syncytia 
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and multinucleated giant cell formation in culture and transform T-lymphocytes 
in vitro, in vivo infection with either of these type-C retroviruses may result in 
abnormally proliferative or functionally impaired helper (CD4+) T-lymphocytes. 
In contrast, HTLV-III (now named HIV-I) and HIV-II, the retroviruses 
associated with the acquired immunodeficiency syndrome, are lentiviruses and 
as such are genetically distinct from HTLV-I and HTLV-II and are cytopathic to 
CD4+ T-lymphocytes in vitro [Desgranges et al, 1989]. 
Evidence for Leukemogenesis 
Following initial isolations of HTLV-I from patients with CTCL, it was 
demonstrated that HTLV-I could not be isolated from most CTCL patients and 
that many HTLV-I isolates were from patients who did not clinically have CTCL 
[Gallo, 1985]. The role of HTLV-I in human disease remained unclear until 
reports from Japan implicated the virus in the pathogenesis of adult T-cell 
leukemia (ATL). First described in 1977 by Takatzuki, ATL is an aggressive 
leukemia of malignant helper (CD4+) T-lymphocytes that is frequently 
associated with hypercalcemia and dermatologic manifestations [Uchiyama et 
al, 1977]. The incidence in Japan of ATL follows a north to south gradient with 
heaviest concentration on two southern islands, a pattern that is consistent with 
an infectious etiology [Yoshida and Seiki, 1990]. 
ATL is localized in three separate areas of the world: southwestern 
Japan [Uchiyama et al, 1977], the West Indies [Blattner et al, 1982], and central 
Africa [Hunsmann et al, 1983]. Because HTLV-I is endemic in these same 
areas, an association between HTLV-I and ATL was suspected. Sera from all 
ATL patients initially tested contained antibodies to HTLV-I, and monoclonal 
antibodies generated against HTLV-I proteins reacted with cultured ATL cells 
[Hinuma et al, 1981; Kalyanaraman et al, 1982]. A type-C retrovirus was 
isolated in 1984 from T-cell cultures of Japanese patients with adult T-cell 
leukemia (ATL) that was subsequently demonstrated to be identical to HTLV-I 
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isolates from the United States [Yoshida et al, 1984]. 
Additional evidence supporting a role for HTLV-I in leukemogenesis 
followed. The virus was isolated from a Japanese-American with a T-cell 
leukemia, and Caribbean born blacks who were recognized to have a 
concentration of T-cell leukemias were all found to be HTLV-I positive 
[Gallo,1985]. Studies of the biology and molecular virology of cell lines from 
ATL patients revealed that ATL is a disease of CD4+ helper T-cells. All leukemic 
cells from any individual ATL patient contained HTLV-I provirus integrated at the 
same genomic site, suggesting that infection occured prior to transformation of 
these cells into a lymphoproliferative clone [Yoshida et al, 1984]. Groups in 
Japan and the U.S. both showed that cultured ATL cells could transform a 
normal CD4+ cell line into an immortal clone [Wong-Staal and Gallo, 1985; 
Yamamoto and Hinuma, 1985]. Miyoshi was then able to induce malignancies 
in hamsters by inoculating cell lines transformed with HTLV-I from ATL patients 
[Miyoshi et al, 1984]. Furthermore, a virus closely related to HTLV-I, simian 
T-lymphotropic virus type I, was isolated from African green monkeys and found 
to be associated with Simian malignant lymphoma [Hunsmann et al, 1983, 
Miyoshi et al, 1982]. 
Biological Properties of HTLV-I Transformed Cells 
Both ATL cell lines and cell lines immortalized by HTLV-I infection in vitro 
are predominately CD4+ helper T-cells that spontaneously express high levels 
of interleukin-2 (IL-2) receptor and grow in culture as multinucleated giant cells 
with lobulated nuclei. These cultures continue to grow in the absence of IL-2 or 
may require only low concentrations of exogenously added IL-2. Normal T-cell 
lines, in contrast, require phytohemagglutinin activation to induce IL-2 receptor 
expression, grow in culture as single cells, and require exogenously added IL-2 




HTLV-I contains a magnesium-dependent reverse transcriptase, high 
molecular weight RNA, and both internal core and envelope glycoproteins. In 
contrast with other mammalian type-C retroviruses, HTLV-I has a small sized 
core protein (p24) and a glycosylated transmembrane protein (gp41) [Reitz et 
al, 1981; Kalyanaraman et al, 1981]. 
Like all type-C retroviruses, the HTLV-I genome contains 5' and 3' long 
terminal repeats (LTR's) and gag, pol. and env genes that encode viral 
structural proteins, reverse transcriptase, and transmembrane glycoproteins 
respectively. The aag gene encodes a 53,000 dalton polypeptide (p53) that is 
proteolytically cleaved into pi 9, p24, and pi 5 internal structural proteins. The 
product of the eoi gene is a magnesium dependent reverse transcriptase (RT) 
that is synthesized in infected cells as a gag-pol product and detected as a 
180,000-200,000 dalton polyprotein. The env gene product is a 62,000 dalton 
glycosylated protein that can be cleaved into outer envelope (gp46) and 
transmembrane (gp 21) proteins [Desgranges et al, 1989] (Figure 4). 
HTLV-I has no known viral oncogene [Seiki et al, 1984b]. Furthermore, 
although all ATL cells from an individual patient contain HTLV-I provirus 
integrated at the same site, there is not a common region of proviral integration 
in leukemic cells from different ATL patients [Seiki et al, 1984a]. HTLV-I thus 
does not induce leukemogenesis by viral oncogenesis or insertional 
mutagenesis (in which proviral integration into a specific chromosomal locus 
activates an adjacent cellular oncogene- a cis-acting function). A trans-actina 
viral function mediated by viral proteins was hypothesized. 
HTLV-I has a genomic segment that is unique to human retroviruses. 
Originally designated ial for transacting transcriptional regulation but now 
termed pX, this sequence is located between the env gene and the 3' LTR and 
has at least two important functions. It encodes regulatory proteins, p40*ax, 
p27rex and p21, that act in trans to exert both positive and negative control on 
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different stages of viral replication (Figure 4). One of these regulatory proteins, 
p40tax, a|so transactivates host cell genes that encode interleukin-2 (IL-2) and 
the alpha subunit of the IL-2 receptor. The alpha subunits thus synthesized are 
able to combine with beta subunits normally present on the surface of T-cells to 
form functional IL-2 receptors [Yoshida, 1990]. HTLV-I mediated transactivation 
results in spontaneous production of IL-2 and expression of IL-2 receptors by 
infected cells. It explains the lack of dependence of HTLV-I transformed cell 
lines on exogenous IL-2 [Inoue et al, 1986]. Production of IL-2 and IL-2 
receptors may be responsible for the early stages of ATL development [Yoshida 
and Seida, 1990]. 
Interestingly, creation of transgenic mice by transfection with the HTLV-I 
tat gene together with an associated promotor resulted in the development of 
multiple mesenchymal soft tissue tumors in the mice. No transfected mice in this 
murine transgenic model developed either leukemia/lymphoma or 




In the initial stage of this project, isolation of HTLV-I was attempted from 
peripheral blood of TSP/HAM patients and controls from the endemic foci of 
Jamaica and Tumaco, Colombia. Heparinized blood was shipped on ice from 
these areas by overnight mail for attempted viral isolation. The establishment of 
a successful system for isolation of HTLV-I from TSP/HAM patients coincided 
with the visit to the National Institutes of Health of a family of three from Tumaco 
with TSP/HAM of varying duration and clinical severity. The methodology used 
to isolate virus from TSP/HAM patients is detailed as it was applied to the 
members of this family. 
Described here are the clinical findings and HTLV-I isolation from a 
married couple and one son who have lived their entire lives in the endemic 
TSP area of Tumaco on the southern Pacific coast of Colombia (Figure 5). They 
were seen by neurologists in Colombia and were brought to the 
Neuroimmunology branch of the Clinical Center, the National Institutes of 
Health, Bethesda, MD, in July 1987 for further evaluation. 
Patient Histories 
Patient 1 
Patient 1, a 43-year-old man, had onset of disease twelve years earlier. 
His first symptoms were itching of the soles of the feet, hip pain on rising in the 
morning, nocturnal muscle cramps, occasional tremor, and numbness of the 
lower limbs. He developed gradually progressive weakness of the lower limbs 
over a period of seven years. He also developed urinary frequency and 
urgency, impotence, and constipation. 
Examination revealed no impairment of intellectual function. His cranial 
nerves were normal. Power was unimpaired in the upper limbs, but he had 
profound weakness of the lower limbs with spasticity, clonus, and bilateral 
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Babinski responses. Hoffmann's sign was positive in both upper limbs, and his 
abdominal reflexes were diminished. Superficial and deep sensation were 
normal. He was able to walk with a spastic gait using one cane. 
His previous medical history and family history were noncontributory. 
Patient 2 
Patient 2, the 44-year-old wife of patient 1, first presented with symptoms 
of the disease eight years earlier when she was unable to expel the placenta 
after child delivery. Soon thereafter she developed numbness and slowly 
progressive weakness of the legs that was more pronounced on the right. More 
recently, her upper limbs became fatigued with continued usage although they 
were not subjectively weak. She also developed burning in the legs, polyuria, 
loss of libido, and constipation. 
On neurologic examination, her intellectual functioning was normal. 
Cranial nerves were intact. She had a spastic paraparesis with generalized 
hyperreflexia, bilateral positive Hoffmann's signs, ankle clonus, and positive 
Babinski responses. In addition, she had marked impairment of vibration sense 
below the second thoracic dermatome. She was able to walk with the aid of one 
cane. 
Her past medical history was significant for seven pregnancies with five 
living children. She was admitted to a hospital 8 years earlier for headache and 
abdominal pain. Two years ago she had herpes zoster affecting the 
mid-thoracic region. 
Patient 3 
Patient 3, the 13-year-old fourth grade son of patients 1 and 2 had a 
three year history of mild nocturnal cramps in his right more than his left leg and 
occasional numbness of his lower limbs. He had no bowel or bladder problems. 
In the past two years he had developed some photophobia and impairment of 
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visual acuity but had been unaware of any decreased ability to study or to play 
soccer. 
On neurological examination, his intellectual function was normal, and 
his cranial nerves were intact. He had hyperreflexia of all four limbs which was 
more marked in the lower limbs. His power was good in the upper limbs, but he 
had minimal weakness of the right lower limb and right ankle clonus. His 
abdominal reflexes were brisk, and both plantar reflexes were extensor. 
Sensation was normal to all modalities. He walked and ran unaided but with a 
suggestion of a mild spastic gait. 
There was no family history of neurologic disease. The extended family 




MATERIALS AND METHODS 
Antibody Determinations: ELISA and Western Immunoblot Assays 
Both serum and CSF from the three patients were tested for IgG 
antibodies to HTLV-I using the Dupont/Biotech enzyme-linked immunosorbent 
assay (ELISA) kit (Biotech Research Labs, E.l. Dupont, Wilmington, DE) 
[Saxinger and Gallo, 1983]. Endpoint titrations were done on both serum and 
CSF. Positive ELISA reactions were confirmed by Western immunoblot using a 
commercially available kit for the detection of antibodies to the major proteins of 
HTLV-I (Biotech research Labs, E.l. Dupont, Wilmington, DE). Serum and CSF 
from each of the three patients were also assayed for IgM antibodies against 
HTLV-I using small columns of quarternary aminoethyl-Sephadex A-50 ion 
exchanger for IgM separation (Isolab Inc., Akron, OH) [Johnson and Libby, 
1988]. Alkaline phosphatase and biotin-labeled goat antibodies to human IgM 
were used for ELISA and western blot procedures, respectively (Kirkegaard and 
Perry Laboratories, Inc., Gaithersburg, MD). 
Cell Separation and Establishment of Cultures 
Peripheral blood lymphocytes from the father and the mother and several 
HTLV-I seronegative disease-free controls from the endemic TSP area of 
Tumaco, Colombia, were separated from heparinized blood by Ficoll-Hypaque 
(Pharmacia Fine Chemicals, Piscataway, NJ) density gradient centrifugation. 
Peripheral blood lymphocytes from the son were obtained by leukopheresis 
(supplied by Dr. Dale McFarlin). The cells were cultured by techniques similar to 
those used to isolate HTLV-I from peripheral blood lymphocytes of ATL patients 
[Poiesz et al, 1980b; Miyoshi et al, 1981]. Minor technical modifications included 
the addition of alpha interferon and both recombinant and cell-derived 
interleukin-2 to the culture medium. 
Cells from all three patients were initially stimulated with 2 jig/ml 
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phytohemagglutinin (Wellcome Diagnostics, Dartford, Eng]) [Nowell, 1960] for 4 
days at a concentration of 1X10® cells/ml in culture medium containing an 
enriched mixture of: RPMI 1640, 20% heat-inactivated fetal bovine serum, 1% 
L-glutamine, 50 pg/ml gentamycin, 5 |ig/ml hydrocortisone, 400 pg/ml sheep 
anti-human alpha interferon (Interferon Sciences, New Brunswick, NJ), 10% 
cell-derived IL-2 (Advanced Biotechnologies, Rockville, MD) and 20 units/ml 
recombinant IL-2 (Amgen, Thousand Oaks.CA) [Popovic et al, 1983]. 
Following stimulation, peripheral blood lymphocytes from the father, the 
mother and controls were either grown independently in culture medium or 
cocultivated with an equal number of phytohemagglutinin stimulated umbilical 
cord blood lymphocytes; peripheral blood lymphocytes from the son were 
cocultivated with cord blood lymphocytes, but were not grown independently 
due to the low number of cells obtained after the leukopheresis. Cultures were 
fed enough culture medium biweekly to maintain a cell density of 1X10® 
cells/ml as monitored by Trypan Blue exclusion. 
A small number of mononuclear cells isolated from 2 ml of cerebrospinal 
fluid from the son were cocultivated with 1X10® cord blood lymphocytes. The 
cocultivation was phytohemagglutinin stimulated for 4 days and then grown in 
culture medium with biweekly feeding as needed. HUT-102 and HUT-78 cell 
lines (obtained from Dr. Prem Sarin, Laboratory of Tumor Cell Biology, National 
Cancer Institute, National Institutes of Health) were maintained as HTLV-I 
positive and negative controls, respectively. 
Preparation of Cord Blood Lymphocytes 
Cord blood lymphocytes were separated from umbilical cord blood 
(Advanced Biotechnologies, Rockville, MD) by Ficoll-Hypaque density gradient 
centrifugation. Separated lymphocytes were then either grown independently 
as a control culture or cocultivated with peripheral blood lymphocytes or 
CSF-derived-mononuclear cells from the patients. 
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Cellular Transformation: Requirement for lnterleukin-2 
Cultures testing positive for HTLV-I by immunofluorescence were 
assayed for transformation by monitoring growth in culture medium free of both 
cell-derived and recombinant exogenous IL-2 [Popovic et al, 1983]. Growth was 
determined by Trypan Blue exclusion. Transformed cultures were reassayed for 
viral antigen by immunoflourescence. 
Detection of the Viral Antigens bv Immunofluorescence 
For detection of viral antigens by indirect immunoflourescence, cultured 
cells were initially centrifuged out of culture medium, washed with phosphate 
buffered saline, air dried onto 8 well Toxoplasmosis slides (2x10^ cells/well), 
and fixed in methanol:acetone (1:1) for 15 min at room temperature. Fixed cells 
were then absorbed for 45 minutes at room temperature with 10% normal goat 
serum in phosphate buffered saline and washed three times with complete 
changes of buffered saline. After air drying, the cells were incubated at 37° C 
for 30 min with either mouse monoclonal antibody to HTLV-I pi 9 or mouse 
monoclonal antibody to HIV p24. The slides were rinsed for 45 min in buffered 
saline/.25% Triton X-100 with 3 changes and air dried. Flourescein 
isothiocyanate labelled goat antibody to mouse immunoglobulin (IgG) (Cappel, 
Cochranvile, PA) was applied for 30 min at 37° C, followed by overnight 
washing in buffered saline/.25% Triton X-100. Slides were then counterstained 
with 0.02% Evans blue, washed for 30 min in buffered saline, mounted, and 
examined with a Zeiss flourescent microscope [Sarin et al, 1985]. 
Reverse Transcriptase Assay Conditions 
To obtain viral pellets for reverse transcriptase testing, 2 ml of culture 
supernatant was mixed with 1.0 mi of 30% polyethlene glycol 8000 and 0.2 ml 
of 4M NaCI. After overnight incubation at 4° C, the mixture was spun at 2500 
RPM for 30 minutes. The pellet was resuspended in 200 (il of cold buffer (50 
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mM Tris.HCI, pH 7.5, 1 mM dithiothreitol, 20% glycerol, 0.35M KCI, 0.25% Triton 
X-100) and vortexed. The sample was frozen at -70° C until ready for use. 
To assay reverse transcriptase activity in the viral pellets, 20 jil of viral 
pellet solution was added to 30 pi of reaction mixture containing 50 mM Tris.HCI 
(pH 7.5), 5 mM dithiothreitol, 100 mM potassium chloride, 0.01% Triton X-100, 
10 ug/ml (dT)15(A)n as template primer and [^H] deoxythymidine triphosphate, 
and incubated for 1 hr at 37° C. The reaction was stopped by adding 10 pi of 
yeast transfer RNA (5mg/ml) and 2 ml of 10% trichloroacetic acid solution 
containing 10 mM sodium pyrophosphate. After standing in ice for at least 15 
minutes, the samples were filtered on millipore filters, washed 5 times with 5% 
trichloroacetic acid, washed once with 70% ethanol and dried under a heat 
lamp. Dried filters were added to scintillation fluid, and radioactivity was 
counted in a 6-scintillation counter [Sarin et al, 1985]. 
Electron Microscopy 
Cell lines were prepared for electron microscopy as follows. Cultures 
were centrifuged gently at 500xg at room temperature. The supernatant was 
discarded and replaced with 2.5% glutaraldehyde freshly prepared in 
cacodylate buffer, pH 7.4. The pellet was then processed as a solid tissue as 
follows: postfixation in 1% osmiun tetroxide for 2 hours, dehydration through 
graded ethanols, clearing in propylene oxide, and embedding in Embed 
[Electron Microscopic Sciences, Fort Washington, PA]. Ultrathin sections were 
stained with lead citrate and uranyl acetate and examined with a Phillips 300 
transmission electron microscope [Liberski et al, 1988]. All electron microscopy 




Antibodies to HTLV-I in Serum and CSF 
Serum and CSF from the three patients contained IgG antibodies against 
HTLV-I as detected by ELISA. Serum and CSF from the father showed the 
highest reactivities, with endpoint titers of 1:2560 in serum and 1:128 in CSF. 
The endpoint titration of antibodies to HTLV-I in the mother was 1:640 in serum 
and 1:8 in CSF while in the son it was 1:320 in serum and 1:4 in CSF. Serum 
from the son but not his parents contained IgM antibody against HTLV-I using 
ELISA at a dilution of 1:10, indicative of a primary humoral response against the 
virus. All samples were confirmed positive against HTLV-I specific proteins by 
Western blot. Serum and CSF from the three family members demonstrated 
antibodies against pi 9, p24, p28, p32, p36, p42, gp46 and p53. In addition 
samples from the mother and father were reactive with pi 5 (Figure 6). 
Among the additional household relatives, HTLV-I antibodies were found 
in the serum of the 46 year old clinically unaffected sister of patient 2 and in the 
serum of her 7 year-old daughter. No other family members were positive. 
Expression of Viral Antigens and Cellular Transformation 
Peripheral blood lymphocytes from the father and mother, peripheral 
blood lymphocyte/cord blood lymphocyte cocultivations from all three patients, 
and the CSF mononuclear cell/cord blood lymphocyte cocultivation from the 
son all showed positive immunofluorescence when labelled with the murine 
monoclonal antibody against HTLV-I pi 9 gag protein. In contrast to the red 
negative staining demonstrated by HTLV-I negative cultures of CBL or HUT-78, 
these cultures exhibited bright yellow-green flourescein isothiocyanate staining 
of pi9 viral antigens in the cytoplasm of infected cells (Figure 7). HTLV-I 
isolates were obtained from peripheral blood lymphocytes of the mother and 
father without cocultivation with cord blood lymphocytes. In contrast, isolation of 
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HTLV-I from peripheral blood lymphocytes of adult T-cell leukemia/lymphoma 
patients has traditionally required cocultivation [Markham and Salahuddin, 
1987]. This requirement for cocultivation differentiates HTLV-I isolated from ATL 
patients from HTLV-I isolated from TSP/HAM patients. We did not attempt virus 
isolation from the peripheral blood lymphocytes of the son without cocultivation 
due to the few cells obtained after the patient's leukopheresis. 
All HTLV-I pi 9 positive cultures from the three family members became 
transformed, as defined by continued proliferation in the absence of exogenous 
IL-2. In addition, the immunoflourescent reactivity of these cultures against 
monoclonal antibody to HTLV pi 9 increased after selection for transformation in 
exogenous IL-2 free medium. The percentage of cells expressing viral antigens 
after transformation increased to as high as 85% (Figure7). 
No cultures demonstrated any reactivity when assayed with a murine 
monoclonal antibody against HIV p24 gag protein either before or after 
transformation testing. Control cultures (cord blood lymphocytes, peripheral 
blood lymphocytes from HTLV-I seronegative controls from Tumaco, and 
peripheral blood lymphocyte/cord blood lymphocyte cocultivation controls) did 
not react with monoclonal antibody against HTLV-I pi 9 before transformation 
testing and died soon after IL-2 was removed from the culture medium. 
Ceil Growth.an.lMoi&bfllQgy 
Following phytohemagglutinin stimulation, all cultures from TSP/HAM 
patients and controls grew initially as predominantly single cell suspensions 
and small clumps of homogeneous lymphoid cells after a week in culture. The 
longevity of the single cell growth phase varied from 13 days (peripheral blood 
lymphocyte/cord blood lymphocyte cocultivation of the son) to 29 days 
(peripheral blood lymphocyte/cord blood lymphocyte cocultivation of the father). 
A change in the culture from single cell organization to growth in large clumps, 
often around a central giant cell, coincided with the expression of viral antigen 
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by the cells as detected by indirect immunoflourescence. 
The percentage of cells in a culture expressing viral antigen by 
immunoflourescence increased in proportion to the amount of cell clumping that 
could be detected micro- and macroscopically. Transformation could not be 
demonstrated until the large clumps formed. These characteristics are similar to 
those that have been described for HTLV-I induced transformation of umbilical 
cord blood lymphocytes by T cell lines from ATL patients [Popovic et al, 1983]. 
In contrast to the morphologic, antigenic, and growth characteristics 
exhibited by virally infected cultures following the single cell growth phase, cord 
blood lymphocyte cultures and cultures of peripheral blood lymphocytes from 
HTLV-I seronegative controls remained in the single cell growth phase for as 
long as they could be carried in culture. 
Ultrastructural Examination 
Electron microscopic examination of infected cell cultures derived from 
the family members revealed virus particles typical of type-C retroviruses 
associated extracellularly with bizarre giant cells. Mature virions measured 
80-140 nm in diameter and were indistinguishable from standard HTLV-I 
viruses. Various stages of virus maturation were seen. Initially, virus formed 
crescent shaped buds at the plasma membrane. As the budding process 
continued, the membrane covered cores were closed, and mature virions were 
released containing electron dense nucleocapsid cores surrounded by a 
smooth envelope (Figure 8). 
Reverse Transcriptase Activity 
Reverse transcriptase activity was assayed in all cultures. In comparison 
to cultures of peripheral blood lymphocytes from HTLV-I seronegative disease 
free controls all of which had radioactivity counts less than 500, cultures from 
the family members had counts ranging from 1778 (CSF mononuclear cell 
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cocultivation from the son) to 6426 (peripheral blood lymphocyte cocultivation 
from the son). Counts from an HTLV-I infected cell line from an ATL patient 
(HUT 102) were consistently greater than 25,000. The background radioactivity 
count ranged from 390 to 423. 
A radioactivity count of three times background was considered 
evidence of viral reverse transcriptase in the culture. Using this criterion, 
reverse transcriptase activity was detected in all cultures in which cells 
expressed viral antigens by immunoflourescence. These levels did not change 
significantly after cultures were grown in the absence of IL-2. Control cultures 
had no detectable enzyme activity. 
It is unclear why the reverse transcriptase levels detected in cultures from 
TSP/HAM patients in this study were much lower than those detected in an ATL 
derived cell line (HUT 102). Subsequent studies performed in our laboratory 
detected significantly higher levels of activity in peripheral blood lymphocyte 
cultures from TSP/HAM patients. The activity in these cultures increased with 
time to a level comparable to that found in cell lines from ATL patients 





A viral etiology has been proposed for many chronic neurological 
diseases including multiple sclerosis, Alzheimer's Disease, and Parkinson’s 
Disease. Essential to implicating a viral pathogen in these diseases is the 
consistent isolation of virus from clinical cases. For diseases of postulated viral 
origin such as multiple sclerosis, the criterion of viral isolation has not been 
repeatedly fulfilled [Johnson, 1982]. In contrast, HTLV-I is etiologically 
associated with TSP/HAM, and, as shown by this study, virus can be 
consistently isolated from patients with this disorder. 
In this investigation, methodology that was previously used to isolate 
HTLV-I from ATL patients was slightly modified to isolate virus from patients with 
TSP/HAM. HTLV-I was isolated from peripheral blood lymphocytes and 
CSF-derived mononuclear cells of a 13-year-old boy with early TSP/HAM and 
from peripheral blood lymphocytes of his 44-year-old mother and 43-year-old 
father, both of whom have disease of longer duration and worse severity. All 
three family members had IgG antibodies to HTLV-I in both serum and CSF, as 
detected by ELISA and confirmed by western immunoblot. 
Successful isolation of a retrovirus was demonstrated by the presence of 
low levels of reverse transcriptase in cell culture supernatants combined with 
the presence of type-C retroviral particles budding off of the surface of infected 
cells as observed by electron microscopy. The retrovirus infecting these cell 
cultures was shown to be HTLV-I by positive staining when assayed by indirect 
immunoflourescence with a murine monoclonal antibody against the pi 9 gag 
protein of HTLV-I. In addition, subsequent studies in our laboratory by 
polymerase chain reaction DNA amplification showed that these isolates were 
definitely HTLV-I and not HTLV-I I [Rodgers-Johnson et al, in preparation]. This 
was important because HTLV-II is an oncornavirus that is structurally and 
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antigenically similar to HTLV-I and may cross react with HTLV-I in some 
serologic assays [Wong-Staai et al, 1985]. HTLV-II is currently not etiologically 
associated with human disease. 
The time in culture required to isolate virus varied inversely with the 
stage of disease of the respective family members. Over double the time in 
culture was required to isolate virus from the father, who first presented with 
TSP in 1975, than was needed to isolate virus from the son, who just recently 
developed upper motor neuron signs. The son represents an early stage of 
TSP, and the possibility that virus is more readily isolated from patients in the 
early stages of the disease should be further investigated. Transmission of 
HTLV-I to the son was most likely vertical via breast milk [Osame et al, 1987], 
but seroepidemiological studies need to be carried out to exclude other 
possible modes of transmission including insect vectors. 
S.iflDjiLcao£g of, the Present Finding? 
This study was particularly significant for several reasons. Using 
methodology very similar to that previously established in the study of ATL, it 
resulted in consistent isolation of virus from TSP/HAM patients. Isolation had 
previously been reported to be difficult, and only individual case reports of 
successful isolation had been described [Hirose et al, 1986; DeFreitas et al, 
1987]. This had also been the case in our laboratory as virus was successfully 
isolated from only 1 of 30 TSP/HAM patients [Rodgers-Johnson, 1988). 
However, applying the methodology that was successful in this study, our 
laboratory has since isolated HTLV-I from TSP/HAM patients from Colombia, 
Jamaica, and Chile [Mora et al, in preparation]; from Jamaicans with 
polymyositis [Rodgers-Johnson et al, in preparation]; and from disease-free 
inhabitants of an HTL'V-1 endemic focus on New Guinea [Yanigahara et al, 
1990]. Additionally, there are less than 10 cases recognized worldwide to date 
of patients who have had both ATL and TSP/HAM, and our laboratory has 
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isolated HTLV-I from one of these cases [Lee et al, 1989]. 
This study was the first isolation of HTLV-I from multiple TSP/HAM 
patients within the same family and the first isolation from an affected child. In 
addition, the 13-year-old son was the first childhood case of TSP/HAM reported 
outside of Japan. TSP/HAM had been reported in Japan in children as young 
as 6 years, but until this study, no childhood cases had been described outside 
of Japan, and virus had never been isolated from a child with TSP/HAM. 
At the time of this investigation, TSP and HAM were thought to be 
separate disorders because of differences in age distribution, climate in which 
they occur, and response to corticosteroids. This study demonstrated that TSP 
and HAM have similar age distributions and thus provided evidence that they 
are not separate entities. The two syndromes were subsequently concluded to 
be identical based on similar clinical, laboratory, and histopathological findings 
[Roman and Osame, 1988]. 
This investigation also resulted in the first report of virally infected cells 
from TSP/HAM that were transformed as defined by continued proliferation in 
the absence of exogenous IL-2. HTLV-I transformed cells have previously been 
characterized by the production of both IL-2 and IL-2 receptors. These cells did 
not require exogenous SL-2 to proliferate. In contrast, non-transformed cells 
required exogenous IL-2 to proliferate, and these cells died when SL-2 was 
removed from the culture medium [Popovic et ai, 1983]. Consistent with these 
criteria for transformation, our virus infected cultures did not require exogenous 
IL-2 to proliferate, and a high percentage of cells in these cultures expressed 
IL-2 receptors as determined by fluorescence activated cell sorting using a 
monoclonal antibody to the IL-2 receptor [Stone, personal communication]. 
Furthermore, removal of exogenous IL-2 from the culture medium significantly 
increased the percentage of cells expressing viral antigens as determined by 
indirect immunofluourescence. It is possible that the selective death of 
non-transformed cells in medium free of exogenous IL-2 enhanced the 
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percentage of cells in the cultures that were virally transformed. 
Further Questions 
Our results raise a number of questions including: 
1) What further evidence exists that HTLV-I has an etiologic role in 
TSP/HAM? 
2) Are the viral isolates from patients with TSP/HAM and ATL the same? 
3) What is the significance of transformation relative to TSP/HAM? 
4) What are the possible pathogenic mechanisms that result in ATL and 
TSP/HAM? 
5) Is TSP/HAM a model for other chronic nervous system disease? 
6) Can HTLV-I be implicated in other disease processes? 
To answer these questions, I will discuss findings that have been 
described by members of our laboratory and other investigators subsequent to 
this study. 
Evidence for an Etioloaic Role of HTLV-I in TSP/HAM 
With the isolation of HTLV-I from TSP/HAM patients, there is now 
compelling evidence implicating a role for HTLV-I in the pathogenesis of 
TSP/HAM. More than 40 geographic clusters of the disease have been 
recognized, all in areas of HTLV-I endemicity. In each of these foci there is a 
high prevalence of antibodies to HTLV-I in CSF and serum of affected patients 
[Rodgers-Johnson et al, 1990]. Early reports of abnormally activated 
lymphocytes with lobulated nuclei in the peripheral blood and CSF and of 
oligoclonal bands with HTLV-I specificity in the CSF of TSP/HAM patients have 
been confirmed repeatedly [Roman, 1990]. Additionally, the visualization by 
electron microscopy of HTLV-l-like particles in spinal cord cells of a Jamaican 
TSP/HAM patient was reported [Liberski et al, 1988]. 
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In addition to the virus isolation in this investigation, isolates were 
obtained from peripheral blood and CSF of TSP/HAM patients by Jacobsen e] 
ai [Jacobson et al, 1988a]. Bhagavati and colleagues subsequently detected 
HTLV-I DNA in peripheral blood and CSF lymphocytes of patients with 
TSP/HAM by enzymatic DNA amplification using the technique of polymerase 
chain reaction [Bhagavati et al, 1988]. More recently, our laboratory detected 
HTLV-I DNA in cell lines from TSP/HAM patients using in situ hybridization 
[Beilke, personal communication]. 
This evidence strongly associates HTLV-I with TSP/HAM. However, the 
mechanism of virally induced pathogenesis is not known. No animal model of 
the disease exists as yet, but our laboratory has initiated experiments in this 
regard in non-human primates, laboratory rodents, and rabbits. 
Comparison of Isolates from TSP/HAM and ATL 
It is still unclear whether the viral isolates from TSP/HAM and ATL are the 
same. Established cell lines from the two diseases have the same in vitro 
growth characteristics consisting of abnormally activated cells with convoluted 
nuclei that express IL-2 receptors and grow in large clumps [McKhann et al, 
1989]. We also found that cell lines from TSP/HAM patients will continue to 
proliferate in the absence of exogenously added IL-2, a property charecteristic 
of ATL cell lines. However, Jacobson ni al reported that isolates obtained by 
activating T-lymphocytes using a monoclonal antibody to the T-cell receptor 
combined with stimulation with exogenous IL-2 were dependent on exogenous 
IL-2 for survival [Jacobson et al, 1988a]. 
Early DNA blotting studies reported that viral isolates from TSP/HAM and 
ATL were identical [Yoshida et al, 1987], More recent work comparing the 
complete DNA sequence of provirus from the two diseases reported greater 
than 97% homology [Tsujimoto et al, 1988]. However, differences between 
TSP/HAM isolates and prototypical HTLV-I from ATL have been detected by 
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restriction mapping [Jacobson et al, 1988a; Sarin et al, 1989], and preliminary 
comparison between DNA that encodes reverse transcriptase in the two 
diseases suggested that up to 5 nucleotide substitutions exist [Bangham et al, 
1988]. 
If in fact strain differences do occur, it remains to be determined whether 
these differences affect the pathogenesis of TSP/HAM versus ATL or whether 
they result from geographic separation of endemic foci. The theory that infection 
by a single strain of HTLV-I may result in two disease processes is supported by 
the recognition to date of several individuals from widely separated geographic 
areas who have developed both TSP/HAM and ATL [Groopman and Ferry, 
1989; Rodgers-Johnson, personal communication]. 
Are Cells Lines from TSP/HAM Patients Transformed? 
The significance of in vitro transformation relative to TSP/HAM must be 
examined. As discussed previously, our cell lines were transformed by the 
criteria of expression of IL-2 receptors by HTLV-I infected cells and continued 
proliferation in the absence of exogenous IL-2 [Popovic et al, 1983]. These 
properties have been shown in ATL-derived cell lines to result from 
transactivation of infected lymphocytes by one of the proteins encoded for by 
the HTLV-I pX region, p40tax. This protein transactivates the genes for IL-2 and 
for the alpha subunit of the IL-2 receptor, resulting in spontaneous production of 
IL-2 and expression of IL-2 receptors [Inoue et al, 1986]. Because infected cells 
produce IL-2 and express IL-2 receptors, they spontaneously proliferate in vitro 
and continue to proliferate when exogenous IL-2 is removed from the cell 
culture medium. In support of transactivation occuring in TSP/HAM, recent 
application of the highly sensitive technique of combining splice excluded 
transcription with polymerase chain reaction genomic amplification has 
demonstrated greatly increased levels of messenger RNA encoding both IL-2 
and the alpha subunit of the IL-2 receptor in peripheral blood lymphocytes from 
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TSP/HAM patients [Greenberg et al, 1990]. 
Whether this process represents true transformation requires 
consideration. In contrast to ATL, a disorder in which monoclonal transformation 
of infected cells results in lymphoproliferation, TSP/HAM is not a clinically 
lymphoproliferative disorder. Transformation of HTLV-I infected cell lines 
implies monoclonal proviral integration. In support of transformation, studies 
have described monoclonal proviral integration in TSP/HAM [Gessain et al, 
1989; Nakamura et al, 1989]. However, others have supported that the virus is 
polyclonally integrated in this disease [Jacobson et al, 1988a; Greenberg et al, 
1989]. One recent study demonstrated that viral isolation from TSP/HAM 
patients produced nontransformed cell lines that died when exogenous IL-2 
was removed from the culture medium [Jacobson et al, 1988a]. 
It is thus possible that cell lines infected with HTLV-I from TSP/HAM 
patients are not transformed in vivo. They may undergo a genetic event in vitro 
resulting in monoclonal proviral integration and transformation. Alternatively, 
these cell lines may be polyclonally infected resulting in persistently activated 
cells that spontaneously proliferate by producing IL-2 and expressing high 
levels of IL-2 receptor without actually being transformed. Consistent with this 
theory is the unusual increase in proliferation of unstimulated peripheral blood 
lymphocytes that has been reported in TSP/HAM patients from Peru [Johnson et 
al, 1988], Colombia [Jacobson et al, 1988b], and Japan [Itoyama et al, 1988]. 
The lymphocytes from these patients express high levels of IL-2 receptor and 
spontaneously proliferate significantly more than corresponding cells from 
HTLV-I seronegative controls, disease free HTLV-I seropositive carriers, or adult 
T-cell leukemia/lymphoma patients [Itoyama et al, 1988]. 
The mechanisms underlying transformation or persistent activation in 
TSP/HAM are not fully understood. Additionally, if HTLV-I infected cells are 
monoclonally transformed in vivo, why this transformation does not result in 
lymphoproliferation is not clear. Further molecular genetic studies of viral 
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isolates are needed to clarify these points. 
PathQflenesis.Q-f-AIL and T$p/HAM 
As evidence accumulates implicating HTLV-I in the etiology of TSP/HAM, 
it is becoming clear that infection by this virus may result in a rapidly 
progressive lymphoproliferative malignancy, a slowly progressive spastic 
paraparesis, both, or neither. The factors controlling disease expression and 
mechanisms of disease pathogenesis are areas of intense scrutiny. 
ATL most likely results from a direct pathogenic effect of HTLV-I in 
combination with other factors. The virus is monoclonally integrated and stably 
present. It can transform target T-lymphocytes both in vivo and in vitro. It is 
postulated that the virus acts as an inducer of ATL risk that when modified by 
the appropriate host genetic factors, virally induced immunosuppressive effects, 
and/or cytogenetic alterations result in progression to ATL. One theory is that 
HTLV-I mediated transactivation of genes encoding IL-2 and the IL-2 receptor is 
responsible for the early stage of ATL development, but that one of the above 
modifying factors is required for progression to the terminally differentiated 
leukemic state [Kramer and Blattner, 1989]. Evidence for this theory includes the 
finding that proviral DNA integrated into ATL cells is methylated and thus not 
being actively expressed [Kramer and Blattner, 1989] and the report that 
expression of HTLV-I pX genes is not required for terminal differentiation of ATL 
cells [Greenberg et al, 1990]. 
The pathogenesis of TSP/HAM is less clearly understood. Possible 
disease mechanisms include direct cytopathic effects of the virus on nervous 
system tissue and both humoral and cell-mediated immunopathogenic 
mechanisms. In support of direct virally induced neural tissue damage, affected 
patients were shown to have intrathecal evidence of HTLV-I infection [Ceroni et 
al, 1988] , and virus was isolated from their CSF mononuclear cells [Jacobson 
et al, 1988; McKhann et al, 1989]. In addition, electron microscopic visualization 
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of unidentified spinal cord cells detected HTLV-l-like particles [Liberski et al, 
1988] . HTLV-I infection of cultured glial cells was also reported [Kim et al, 1988], 
but infection of cultured neurons has yet to be demonstrated. Direct neuropathic 
effects of HTLV-I may be similar to the destruction of neuronal tissue that occurs 
in subacute encephalomyelitis associated with human immunodeficiency virus 
infection [de la Monte et al, 1987]. 
A variety of immune mechanisms may be involved in TSP/HAM 
pathogenesis [Murphy and Blattner, 1989]. Cell mediated possibilities include: 
1) activation of T-effector cells by HTLV-I infected T-helper cells resulting in 
neurologic damage and 2) alteration of T-suppressor cell function by virus 
infection resulting in uncontrolled T-effector cell damage. T-cell dysfunction may 
also induce disease in a permissive way. Popovic showed that HTLV-I infected 
cytotoxic T-lymphocytes are dysfunctional [Popovic et al, 1984]. Deficient 
cytotoxic T-cell function may allow persistent infection by other pathogens, 
antibodies against which may also damage myelin. This humoral molecular 
mimicry could explain the postulated cofactor role of treponemal and borrelial 
infections in endemic foci where a high prevalence of these infections exists 
[Rodgers-Johnson et al, 1990]. An alternate humoral mechanism of 
immunopathogenesis is the cross-reaction against myelin of antibodies to 
HTLV-I [Rudge, 1989]. 
Although direct evidence for an immunopathogenic mechanism of 
disease is lacking, several characteristics of HTLV-I infection in TSP/HAM 
support this process. HTLV-I specific antibodies are found in the CSF of 
TSP/HAM patients [Ceroni et al, 1988], and these antibodies are at much higher 
titers than in patients with ATL or HTLV-I seropositive controls [Rudge et al, 
1989] . The pathology of TSP/HAM is very similar to that seen in ovine visna, an 
immune mediated demyelinating neuro-inflammatory disease [Mani et al, 1969]. 
In this disease, the lentivirus visna maedi infects sheep mononuclear cells. 
Once infected monocytes mature to macrophages, viral replication occurs, and 
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viral antigens are expressed on the cell surface. The resulting immune 
inflammatory response results in disease pathology the severity of which can be 
modified with steroids [Rudge et al, 1989]. Although HTLV-I is an oncornavirus, 
a similar mechanism may be involved. The reported response of patients in 
Japan and Colombia to high dose corticosteroid treatment and the less marked 
inflammatory changes in pathologic specimens following this treatment both 
support an immune mechanism [Rodgers-Johnson et al, 1989]. 
Additional disease manifestations of HTLV-I infection that are associated 
with TSP/HAM also support an immunologic pathogenesis. Systemic 
manifestations of HTLV-I infection that have been found in association with 
TSP/HAM include T-lymphocyte pulmonary alveolitis, uveitis, polymyositis, 
Sjogren's syndrome, arthropathy, necrotizing vasculitis, lymphocytic meningitis, 
and cryoglobulinemia [WHO report, 1989]. All of these processes may be 
immune mediated as a result of HTLV-I infection of T-lymphocytes. 
Recent studies of HLA haplotype-linked immune responsiveness against 
HTLV-I in patients with ATL or TSP/HAM support immune modification of 
disease in both of these processes. Although as yet unconfirmed in other areas 
of the world, Usuku slai in Japan showed that certain human lymphocyte 
antigen (HLA) haplotypes associated with a high immune response to HTLV-I 
were found in 70% of TSP/HAM patients, while different HLA haplotypes 
associated with a low immune response to HTLV-I were found in patients with 
ATL. The authors suggested that high immune responsiveness was one of the 
most important factors in the development of TSP/HAM [Usuku et al, 1988]. 
An equally important question that remains to be answered is why so 
many HTLV-I infected people from areas of viral endemia do not develop either 
TSP/HAM or ATL. The lifetime risk for HTLV-I infected individuals of developing 
ATL has been estimated to be 1%. This risk increases to 3% to 5% for those 
infected before age 20 years [Murphy et al, 1989]. TSP/HAM has much higher 
prevalence in endemic areas than does ATL, but this likely represents the much 
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less rapid clinical course of TSP/HAM. Epidemiologic studies have suggested 
that childhood exposure may be more important for ATL development while 
adult and childhood exposure both confer risk of TSP/HAM development 
[Kramer and Blattner, 1989]. Other than these observations and the HLA 
immunogenetic data discussed above, little is currently known regarding factors 
affecting disease development. 
Is TSP/HAM a model for multiple sclerosis? 
A viral etiology for multiple sclerosis (MS) has been suggested for many 
years, and a number of possible agents have been proposed. Recently, the 
clinical similarity between TSP/HAM and the chronic progressive form of MS 
was recognized and raised the issues of whether these disorders are identical 
and whether HTLV-I plays a role in MS pathogenesis. The association between 
HTLV-I and MS was first reported by Koprowski and colleagues in 1985 who 
described MS patients from both Sweden and the southeastern U.S. who had 
antibodies against the p24 gag antigen of HTLV-I. T-cells from the CSF of these 
patients contained HTLV-I RNA sequences by in Siln hybridization [Koprowski 
et al, 1985]. A second report appearing in 1986 described antibodies reactive to 
the pi 9 and p24 gag proteins of HTLV-I in 40% of Japanese MS patients [Ohta 
et al, 1986]. 
Taken together, the serologic and molecular biologic evidence of HTLV-I 
infection in MS patients combined with the clinical similarity between TSP and 
the chronic progressive form of MS necessitated that viral isolation be 
attempted from MS patients. Successful isolation would allow comparisons to 
be made between HTLV-I isolates from TSP and MS. As a first step in this 
process, virus isolation was attempted from 2 patients with clinical MS and 
serologic evidence of HTLV-I infection as part of this study. HTLV-I infected cell 
lines were not obtained from either of these patients using the same 
methodology that was utilized to isolate virus from TSP/HAM patients. 
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Failure to isolate virus from MS patients was not surprising considering 
the growing body of information that does not support a role for prototypical 
HTLV-I in MS. Poser reviewed the data concerning HTLV-I in MS pathogenesis 
and concluded that it is "highly unlikely that HTLV-I can be implicated as the 
etiologic agent of multiple sclerosis" [Poser, 1989]. More recently, preliminary 
results from a large blinded study looking at the role of HTLV-I in MS using 
polymerase chain reaction DNA amplification detected HTLV-I genomic 
segments in only 14 of 1368 peripheral blood lymphocyte samples from MS 
patients [Greenberg, personal communication]. 
HTLV-I and Other Diseases 
HTLV-I has recently been associated with other disease processes 
including polymyositis and malignant fibrous histiocytoma. Sera of 11 of 13 
biopsy proven cases of Jamaican polymyositis were reported to have high titers 
of antibodies to HTLV-I [Morgan et al, 1989]. HTLV-I infected patients with 
TSP/HAM and polymyositis had been previously described [Goudreau et al, 
1988; Bhagavati et al, 1988], but this report associated HTLV-I with polymyositis 
alone. The authors suggested that HTLV-I be considered as a cause of 
polymyositis in areas of virus endemia. This etiologic association was 
supported by the recent isolation of virus from a Jamaican polymyositis patient 
[Rodgers-Johnson et al, in preparation]. Further studies are needed to 
determine whether this association is significant relative to disease 
pathogenesis. 
A case was also reported of malignant fibrous histiocytoma in an 
individual with a history of both TSP/HAM and ATL [Lee et al, 1989]. Attempts to 
demonstrate HTLV-I antigen in sections of this patient's sarcoma were 
unsuccessful. However, the authors concluded that this tumor may have 
resulted from HTLV-I infection because it histopathologically was very similar to 
the multiple mesenchymal tumors that develop in transgenic mice transfected 
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with the iai gene of HTLV-I [Nerenberg et al, 1987]. Additionally, the chance of a 
malignant fibrous histiocytoma occurring randomly in a patient in association 
with TSP/HAM and ATL was calculated to be 1 in 101®. If this tumor did result 
from HTLV-I infection, it further expands the spectrum of disease that may result 




In a remarkably short period of time, a chronic neurologic disease of 
strikingly high incidence in certain areas of the world that was previously an 
epidemiologic mystery has been clarified. As HTLV-I is now recognized as the 
probable causative agent of TSP/HAM in addition to ATL, public health 
measures have begun to decrease transmission of the virus. Mandatory 
screening of all blood donors has begun in Japan and is being carried out in 
selected areas of the United States. In addition, recommendations against 
breast feeding by infected mothers have been made although they are 
impractical in many countries. The discovery that a virus known to cause 
leukemia also is implicated in the development of a chronic neurologic disorder 
by different pathogenic mechanisms raises the possibility that other infectious 




Table 1. Prevalence of Neurological Signs and Symptoms in 301 
TSP patients. 
Sian/Svmptom % Affected 
Weakness/spasticity (lower limbs) 100 
Urinary disturbance (e.g. frequency, urgency) 71 
Constipation 65 
Impairment of postural/vibratory sense 56 
Positive jaw jerk 30 
Impairment of light touch/pain sensation 28 
Abnormal pupils 20 
Muscle wasting 14 
Visual impairment (sometimes optic atrophy) 14 
Nerve deafness 9 
Cerebellar signs (first noticed in upper limbs) 8 
Adapted with permission from Rodgers-Johnson, 1989a 
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Table 2. Prevalence of IgG Antibodies to HTLV-I in serum and/or 
CSF of patients with TSP/HAM and in the general adult population 
in areas of endemicity. 
% IgG Antibodies to HTLV-I 




Jamaica 89 91 3-5 
Colombia 96 98 10 
Martinique 100 80 4 
Trinidad 87 87 4 
Seychelles — 85 12 
Japan (Kagoshima) 100 100 16 
Modified with permission from Rodgers-Johnson et al, 1988b. 
Antibody reactivity detected by enzyme-linked immunosorbent assay (ELISA) 
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Figure 1. Worldwide distribution of tropical ataxic neuropathy (TAN) and 
tropical spastic paraparesis (TSP). Blackened areas indicate regions where a 
high prevalence of HTLV-1 antibodies has been detected in TSP/HAM 
patients, while hatched regions are endemic TSP/HAM foci where HTLV-1 
seropositivity has not been fully tested. [Courtesy of Dr. Pamela 
Rodgers-Johnson, Laboratory of Central Nervous System Studies, National 
Institutes of Health]. 
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Figure 2. Histopathologic findings from spinal cord tissue of a 40-year-old 
Jamaican woman with TSP/HAM who died of a massive pulmonary embolism 
5 years after the onset of disease. The left photomicrograph illustrates 
perivascular cuffing of a predominately lymphocytic infiltrate of mononuclear 
cells in the meninges and scattered in the gray and white matter of the 
parenchyma (hematoxylin and eosin, XI6.5). The right panel shows 
prominent demyelination of the lateral column of the spinal cord (Luxol fast 
blue, XI 6.5). [Courtesy of Dr. Pedro Piccardo, Laboratory of Central Nervous 
System Studies, National Institites of Health]. 
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Figure 3. Light microscopic examination of peripheral blood from a 
66-year-old Jamaican female with a 13 year history of TSP/HAM. The cell 
prominently displayed is an abnormal giant lymphocyte with convoluted 
rosette type nuclei. These cells, which are found in both CSF and peripheral 
blood of TSP/HAM patients, are morphologically similar to HTLV-I infected 
lymphocytes seen in peripheral blood of adult T-cell leukemia patients. 
[Courtesy of Dr. Prem Sarin, Laboratory of Tumor Cell Biology, National 
Institutes of Health]. 
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Figure 5. Three members of a Colombian family from the endemic 
TSP/HAM focus of Tumaco. The father, mother, and son have TSP/HAM of 
varying clinical severity and duration, and all three have IgG antibodies to 
HTLV-I in their serum and CSF. [Courtesy of Dr. Carlos Mora, Laboratory of 
Central Nervous System Studies, National Institutes of Health]. 
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Figure 6. Western immunoblot for detection of antibodies against 
polypeptides of human T-lymphotropic virus type-1 (HTLV-I). Human positive 
and negative refreence sera (left) are compared with serum and 
cerebrospinal fluid (CSF) of the father, mother, and son. Labelled bands 
include pi 9 and p24 gag internal structural proteins, gag precursor proteins 
p36 and p53, and the outer envelope glycoprotein gp46. 
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Figure 7. Immunoflourescence of cultured cells from TSP/HAM patients and 
controls following reaction with flourescein-labelled mouse monoclonal 
antibody to HTLV-I pi9 antigen. A) Negative staining of cultured peripheral 
blood lymphocytes from an HTLV-I seronegative disease free control. B) 
Granular intracytoplasmic immunoflourescent staining of cocultivated 
peripheral blood lymphocytes from the son. C) Eight days following removal of 
exogenous interleukin-2 (IL-2) from growth medium of culture assayed in B), 
immunoflourescent reactivity and the percentage of cells expressing viral 
antigens has increased markedly. D) Similar staining pattern demonstrating 




Figure 8. Electron microscopic examination of cultured peripheral blood 
lymphocytes from the mother showing: A) Extracellular mature virions that 
resemble HTLV-I like type-C particles with rounded nucleoid cores 
(arrowheads). B) Virion budding from the surface of infected cell (arrowhead). 
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